Boston Scientific Q4 EPS off 25%
- Boston Scientific (NYSE:BSX) Q4 results ($M): Total Revenues: 1,887 (+2.7%); Cardiovascular: 745 (+5.1%); Rhythm Management: 527 (+1.7%); MedSurg: 614 (+0.8%); CRM: 275 (+2.2%); Coronary Stent Systems: 125 (+11.6%).
- COGS: 559 (+07%); R&D Expense: 208 (-3.7%); SG&A Expense: 753 (+4.0%); Net Income: 87 (-19.4%); EPS: 0.06 (-25.0%); Quick Assets: 587 (+170.5%).
- Gross Profit: 1,327 (+3.6%); COGS: 29.6% (-1.9%); Gross Margin: 70.4% (+0.8%); Operating Earnings: 366 (+7.3%); Operating Earnings Yield: 19.4% (+4.5%); Net Earnings Yield: 4.6% (-21.6%).
- 2015 Guidance: Revenues: $7.3B - 7.5B; EPS: $0.42 - 0.48; Non-GAAP EPS: $0.88 - 0.92.
- Q1 Guidance: Revenues: $1.74B - 1.80B; EPS: $0.07 - 0.11; Non-GAAP EPS: $0.19 - 0.21.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
